U.S. FDA Approves PADCEV(R) plus Keytruda(R) for Certain Patients with Bladder Cancer

(TSE: 4503, President and CEO: Naoki Okamura, "Astellas") today announced that the U.S. Food and Drug Administration (FDA) has approved PADCEV (R) (enfortumab vedotin-ejfv), a Nectin-4 directed ...